Altogether, these results suggest that PKF115-584 and pyrvinium can be combined with FTS in CRC cells harbouring concomitant Wnt/KRAS genetic abnormalities, to achieve better therapeutic effects. This evidence concerns the gene AKTIP and colorectal carcinoma.